Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
MODERNA, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 103.29 USD | +3.01% | +3.30% | -42.50% | |
| Sep. 29 | Around 1.8 million Americans received COVID shots last week -IQVIA | RE |
| Sep. 28 | Canada Approves Use of Pfizer and BioNTech Covid-19 Booster | DJ |
Financials (USD)
| Sales 2023 * | 7,189 M | Sales 2024 * | 6,217 M | Capitalization | 39 311 M |
|---|---|---|---|---|---|
| Net income 2023 * | -1,508 M | Net income 2024 * | -1,901 M | EV / Sales 2023 * | 4,48x |
| Net cash position 2023 * | 7,073 M | Net cash position 2024 * | 5,850 M | EV / Sales 2024 * | 5,38x |
| P/E ratio 2023 * | -26,3x | P/E ratio 2024 * | -20,9x | Employees | - |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 90.33% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +3.01% | ||
| 1 week | +3.30% | ||
| Current month | -8.65% | ||
| 1 month | -10.95% | ||
| 3 months | -15.41% | ||
| 6 months | -30.58% | ||
| Current year | -42.50% |
1 week
97.11
104.74
1 month
97.11116.60
Current year
95.02207.51
1 year
95.02217.25
3 years
65.49497.49
5 years
11.54497.49
10 years
11.54497.49
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-29 | 103.29 | +3.01% | 4,202,908 |
| 23-09-28 | 100.27 | +0.83% | 2,034,489 |
| 23-09-27 | 99.44 | +1.35% | 2,367,422 |
| 23-09-26 | 98.12 | -0.05% | 2,888,397 |
| 23-09-25 | 98.17 | -1.82% | 2,908,970 |
Delayed Quote Nasdaq, September 29, 2023 at 04:00 pm EDT
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2023-11-01
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
103.29USD
Average target price
182.39USD
Spread / Average Target
+76.58%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -42.50% | 39 311 M $ | |
| +115.74% | 91 M $ | |
| +0.99% | 50 M $ | |
| +36.03% | 247 M $ | |
| -.--% | 1 789 M $ | |
| -54.24% | 60 M $ | |
| -12.06% | 620 M $ | |
| -39.18% | 796 M $ | |
| -59.44% | 132 M $ | |
| +22.70% | 897 M $ |
